Am. J. Respir. Crit. Care Med., Volume 158, Number 3, September 1998, 857-861

Risk of Emergency Care, Hospitalization, and ICU Stays for Acute Asthma among Recipients of Salmeterol

STEPHAN F. LANES, LEE L. LANZA, and CHARLES E. WENTWORTH III

Epidemiology Resources Inc., Newton Lower Falls, Massachusetts

We used automated health insurance claims records of a New England insurer to assess the relation between salmeterol and severe nonfatal asthma. We identified 61,712 members who received a -agonist from January 1, 1993 to August 31, 1995, including 2,708 recipients of salmeterol. Compared with recipients of other -agonists, future salmeterol recipients had higher rates of asthma hospitalization and dispensings of asthma medications during the year before they received salmeterol. We selected as a comparison group 3,825 recipients of sustained-release theophylline. We defined a baseline period as the year before the start of the follow-up period, and we characterized patients according to age, sex, calendar period, presence of baseline hospitalizations for asthma, presence of chronic obstructive pulmonary disease (COPD), and baseline dispensings of asthma medications. After adjusting for baseline factors, incidence rates of severe asthma in the salmeterol group were not elevated for emergency care (rate ratio estimate [RR] = 0.69, 95% confidence intervals [CI] = 0.42, 1.11), hospitalization (RR = 1.09, 95% CI = 0.60, 1.98), or intensive care unit (ICU) stays (RR = 0.81, 95% CI = 0.25, 2.62). We conclude that salmeterol was prescribed preferentially to high-risk patients and, after adjusting for baseline risk, salmeterol recipients did not have a greater risk than theophylline recipients of severe nonfatal asthma.

This article has been cited by other articles:

				M. Wijesinghe, M. Weatherall, K. Perrin, M. Harwood, and R. Beasley Risk of mortality associated with formoterol: a systematic review and meta-analysis Eur. Respir. J., October 1, 2009; 34(4): 803 - 811. [Abstract] [Full Text] [PDF]

				D. M. LANG New asthma guidelines emphasize control, regular monitoring Cleveland Clinic Journal of Medicine, September 1, 2008; 75(9): 641 - 653. [Abstract] [Full Text] [PDF]

				M Wijesinghe, K Perrin, M Harwood, M Weatherall, and R Beasley The risk of asthma mortality with inhaled long acting {beta}-agonists Postgrad. Med. J., September 1, 2008; 84(995): 467 - 472. [Abstract] [Full Text] [PDF]

				E. Bateman, H. Nelson, J. Bousquet, K. Kral, L. Sutton, H. Ortega, and S. Yancey Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events Ann Intern Med, July 1, 2008; 149(1): 33 - 42. [Abstract] [Full Text] [PDF]

				J. Chang and Z. Mosenifar Differentiating COPD From Asthma in Clinical Practice J Intensive Care Med, September 1, 2007; 22(5): 300 - 309. [Abstract] [PDF]

				H. S. Nelson, S. T. Weiss, E. R. Bleecker, S. W. Yancey, P. M. Dorinsky, and the SMART Study Group The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Chest, January 1, 2006; 129(1): 15 - 26. [Abstract] [Full Text] [PDF]

				J. F. Donohue Therapeutic Responses in Asthma and COPD: Bronchodilators Chest, August 1, 2004; 126(2_suppl_1): 125S - 137S. [Abstract] [Full Text] [PDF]

				J. F. Donohue The Expanding Role of Long-Acting {beta}-Agonists Chest, August 1, 2000; 118(2): 283 - 285. [Full Text] [PDF]

				M. Cazzola, C. F. Donner, and M. G. Matera Long acting beta 2 agonists and theophylline in stable chronic obstructive pulmonary disease Thorax, August 1, 1999; 54(8): 730 - 736. [Full Text]